


Claims:

1. A compound selected from the group consisting of:

compounds of formula (I)



wherein

U is O or a lone pair,

V is a) O, S, NR<sup>1</sup>, or CH<sub>2</sub>, and L is lower-alkylene or lower-alkenylene,

b) -CH=CH- or -C≡C-, and L is lower-alkylene or a single bond,

W is CO, COO, CONR<sup>2</sup>, CSO, CSNR<sup>2</sup>, SO<sub>2</sub>, or SO<sub>2</sub>NR<sup>2</sup>,

X is hydrogen or one or more optional halogen and/or lower-alkyl substituents,

m is 1 or 2,

n is 0 to 7,

A<sup>1</sup> is hydrogen, lower-alkenyl, or lower-alkyl optionally substituted by hydroxy, lower-alkoxy, or thio-lower-alkoxy,

A<sup>2</sup> is cycloalkyl, cycloalkyl-lower-alkyl, lower-alkenyl, lower-alkinyl, or lower-alkyl optionally substituted by hydroxy, lower-alkoxy or thio-lower-alkoxy,

A<sup>3</sup> and A<sup>4</sup> independently from each other are hydrogen or lower-alkyl, or

A<sup>1</sup> and A<sup>2</sup> or A<sup>1</sup> and A<sup>3</sup> are bonded to each other to form a ring and -A<sup>1</sup>-A<sup>2</sup>- or

-A<sup>1</sup>-A<sup>3</sup>- are lower-alkylene or lower-alkenylene, optionally substituted by R<sup>3</sup>, in which one -CH<sub>2</sub>- group of -A<sup>1</sup>-A<sup>2</sup>- or -A<sup>1</sup>-A<sup>3</sup>- can optionally be replaced by NR<sup>4</sup>, S, or O,

A<sup>5</sup> is cycloalkyl, cycloalkyl-lower-alkyl, heterocycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, lower-alkyl optionally substituted with hydroxy or lower-alkoxy, alkenyl optionally substituted with hydroxy, or alkadienyl optionally substituted with hydroxy,

R<sup>3</sup> is hydroxy, lower-alkoxy, thio-lower-alkoxy, N(R<sup>5</sup>,R<sup>6</sup>), or lower-alkyl optionally substituted by hydroxy,


R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> independently from each other are hydrogen or lower-alkyl;

pharmaceutically acceptable salts of compounds of formula (I); and

pharmaceutically acceptable esters of compounds of formula (I).

2. The compound according to claim 1, wherein U is a lone pair.
3. The compound according to claim 2, wherein V is O or CH<sub>2</sub>, and L is lower-alkylene or lower-alkenylene.
4. The compound according to claim 2, wherein V is -C≡C- and L is lower-alkylene or a single bond.
5. The compound according to claim 3, wherein n is 0.
6. The compound according to claim 3, wherein A<sup>1</sup> is lower-alkyl.
7. The compound according to claim 6, wherein A<sup>1</sup> is methyl or ethyl.
8. The compound according to claim 3, wherein A<sup>2</sup> is lower-alkenyl, or lower-alkyl optionally substituted by hydroxy or lower-alkoxy.
9. The compound according to claim 8, wherein A<sup>2</sup> is 2-propenyl or 2-hydroxy-ethyl.
10. The compound according to claim 3, wherein A<sup>1</sup> and A<sup>2</sup> are bonded to each other to form a ring and -A<sup>1</sup>-A<sup>2</sup>- is lower-alkylene or lower-alkenylene, optionally substituted by R<sup>3</sup>, in which one -CH<sub>2</sub>- group of -A<sup>1</sup>-A<sup>2</sup>- can optionally be replaced by NR<sup>4</sup>, S, or O, wherein R<sup>3</sup> and R<sup>4</sup> are as defined in claim 1.
11. The compound according to claim 3, wherein A<sup>3</sup> is hydrogen.

12. The compound according to claim 11, wherein A<sup>4</sup> is hydrogen.
13. The compound according to claim 3, wherein A<sup>5</sup> is cycloalkyl, cycloalkyl-lower-alkyl, heterocycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, or lower-alkyl optionally substituted with hydroxy or lower-alkoxy.
14. The compound according to claim 13, wherein A<sup>5</sup> is phenyl or benzyl, optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluorine and chlorine, or wherein A<sup>5</sup> is lower-alkyl.
15. The compound according to claim 14, wherein A<sup>5</sup> is phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, butyl, or pentyl.
16. The compound according to claim 3, wherein W is COO, CONR<sup>2</sup>, CSO, or CSNR<sup>2</sup>, and R<sup>2</sup> is hydrogen.
17. The compound according to claim 3, wherein X is hydrogen.
18. The compound according to claim 3, wherein X is fluorine.
19. A compound according to claim 2, selected from the group consisting of:  
5-[5-(Allyl-methyl-amino)-pent-1-ynyl]-6-fluoro-2,3-dihydro-indole-1-carboxylic acid 4-chloro-phenyl ester,  
5-{5-[Ethyl-(2-hydroxy-ethyl)-amino]-pent-1-ynyl}-6-fluoro-2,3-dihydro-indole-1-carboxylic acid 4-chloro-phenyl ester,  
6-Fluoro-5-[5-(methyl-propyl-amino)-pentyl]-2,3-dihydro-indole-1-carboxylic acid phenyl ester,  
and pharmaceutically acceptable salts or pharmaceutically acceptable esters thereof.
20. A compound selected from the group consisting of:  
  
compounds of formula (VII)



wherein

V is O or CH<sub>2</sub>;

L is lower-alkylene or lower-alkenylene;

W is COO, CONH, CSNH or CSO;

A<sup>1</sup> is hydrogen or lower-alkyl;

A<sup>2</sup> is lower alkyl or lower alkenyl;

m is 1 or 2; and

A<sup>5</sup> is lower alkyl, phenyl or lower alkyl phenyl, wherein the phenyl group is optionally substituted with halogen;

pharmaceutically acceptable salts of compounds of formula (VII); and

pharmaceutically acceptable esters of compound of formula (VII).

21. The compound according to claim 20, wherein V is CH<sub>2</sub>.
22. The compound according to claim 21, wherein m is 1.
23. The compound according to claim 22, wherein W is COO.
24. The compound according to claim 23, wherein the compound of formula (VII) is 5-[5-(Allyl-methyl-amino)-pentyl]-2,3-dihydro-indole-1-carboxylic acid 4-chloro-phenyl ester.
25. The compound according to claim 24, which is 5-[5-(Allyl-methyl-amino)-pentyl]-2,3-dihydro-indole-1-carboxylic acid 4-chloro-phenyl ester.
26. The compound according to claim 22, wherein W is CONH.


27. The compound according to claim 26, wherein the compound of formula (VII) is 5-[5-(Allyl-methyl-amino)-pentyl]-2,3-dihydro-indole-1-carboxylic acid (4-fluoro-phenyl)-amide.
28. The compound according to claim 27, which is 5-[5-(Allyl-methyl-amino)-pentyl]-2,3-dihydro-indole-1-carboxylic acid (4-fluoro-phenyl)-amide.
29. The compound according to claim 22, wherein W is CSNH.
30. The compound according to claim 29, wherein the compound of formula (VII) is 5-[5-(Allyl-methyl-amino)-pentyl]-2,3-dihydro-indole-1-carbothioic acid (4-chloro-phenyl)-amide.
31. The compound according to claim 30, which is 5-[5-(Allyl-methyl-amino)-pentyl]-2,3-dihydro-indole-1-carbothioic acid (4-chloro-phenyl)-amide.
32. The compound according to claim 29, wherein the compound of formula (VII) is 5-[5-(Allyl-methyl-amino)-pentyl]-2,3-dihydro-indole-1-carbothioic acid 4-chloro-benzylamide.
33. The compound according to claim 32, which is 5-[5-(Allyl-methyl-amino)-pentyl]-2,3-dihydro-indole-1-carbothioic acid 4-chloro-benzylamide.
34. The compound according to claim 22, wherein W is CSO.
35. The compound according to claim 34, wherein the compound of formula (VII) is 5-[5-(Allyl-methyl-amino)-pentyl]-2,3-dihydro-indole-1-carbothioic acid O-(4-chloro-phenyl) ester.
36. The compound according to claim 35, which is 5-[5-(Allyl-methyl-amino)-pentyl]-2,3-dihydro-indole-1-carbothioic acid O-(4-chloro-phenyl) ester.

37. The compound according to claim 34, wherein the compound of formula (VII) is 5-[5-(Allyl-methyl-amino)-pentyl]-2,3-dihydro-indole-1-carbothioic acid O-(4-fluoro-phenyl) ester.
38. The compound according to claim 37, which is 5-[5-(Allyl-methyl-amino)-pentyl]-2,3-dihydro-indole-1-carbothioic acid O-(4-fluoro-phenyl) ester.
39. The compound according to claim 21, wherein m is 2.
40. The compound according to claim 20, wherein V is O.
41. The compound according to claim 40, wherein m is 1.
42. The compound according to claim 41, wherein W is COO.
43. The compound according to claim 41, wherein W is CONH.
44. The compound according to claim 41, wherein W is CSNH.
45. The compound according to claim 44, wherein the compound of formula (VII) is 5-[4-(Allyl-methyl-amino)-butoxy]-2,3-dihydro-indole-1-carbothioic acid 4-fluoro-benzylamide.
46. The compound according to claim 45, which is 5-[4-(Allyl-methyl-amino)-butoxy]-2,3-dihydro-indole-1-carbothioic acid 4-fluoro-benzylamide.
47. The compound according to claim 44, wherein the compound of formula (VII) is 5-[4-(Allyl-methyl-amino)-butoxy]-2,3-dihydro-indole-1-carbothioic acid butylamide.
48. The compound according to claim 47, which is 5-[4-(Allyl-methyl-amino)-butoxy]-2,3-dihydro-indole-1-carbothioic acid butylamide.

49. The compound according to claim 44, wherein the compound of formula (VII) is 5-[4-(Allyl-methyl-amino)-butoxy]-2,3-dihydro-indole-1-carbothioic acid (2-methyl-butyl)-amide.
50. The compound according to claim 49, which is 5-[4-(Allyl-methyl-amino)-butoxy]-2,3-dihydro-indole-1-carbothioic acid (2-methyl-butyl)-amide.
51. The compound according to claim 41, wherein W is CSO.
52. The compound according to claim 51, wherein the compound of formula (VII) is 5-[4-(Allyl-methyl-amino)-butoxy]-2,3-dihydro-indole-1-carbothioic acid O-(4-chloro-phenyl) ester.
53. The compound according to claim 52, which is 5-[4-(Allyl-methyl-amino)-butoxy]-2,3-dihydro-indole-1-carbothioic acid O-(4-chloro-phenyl) ester.
54. The compound according to claim 40, wherein m is 2.
55. The compound according to claim 54, wherein W is COO.
56. The compound according to claim 54, wherein W is CONH.
57. The compound according to claim 56, wherein the compound of formula (VII) is 6-[4-(Allyl-methyl-amino)-but-2-enyloxy]-3,4-dihydro-2H-quinoline-1-carboxylic acid (4-fluoro-phenyl)-amide.
58. The compound according to claim 57, which is 6-[4-(Allyl-methyl-amino)-but-2-enyloxy]-3,4-dihydro-2H-quinoline-1-carboxylic acid (4-fluoro-phenyl)-amide.
59. The compound according to claim 54, wherein W is CSNH.
60. The compound according to claim 54, wherein W is CSO.


61. A process for the manufacture of compounds according to claim 1, which process comprises:

a) reacting a compound of formula (II)




with a compound  $(A^1, A^2, U)N-C(A^3, A^4)-L-M$ , wherein V is O, S or  $NR^1$ , M is mesylate, tosylate, triflate, Cl, Br or I, and U,  $A^1$ ,  $A^2$ ,  $A^3$ ,  $A^4$ ,  $A^5$ , L, W, X, m, n and  $R^1$  are as defined in claim 1, or wherein HV is mesylate, tosylate, triflate, Cl, Br or I, and M is OH, SH or  $NHR^1$ , and  $R^1$  is as defined in claim 1,

or b) reacting a compound of formula (III)




with a compound  $NHA^1, A^2$ , wherein M is mesylate, tosylate, triflate, Cl, Br or I, and  $A^1$ ,  $A^2$ ,  $A^3$ ,  $A^4$ ,  $A^5$ , L, V, W, X, m and n are as defined in claim 1,

or c) reacting a compound of formula (IV)




with a compound  $(A^1, A^2, U)N-C(A^3, A^4)-L-C\equiv CH$ , wherein M is Br or  $F_3CO_2SO$ , and U,  $A^1$ ,  $A^2$ ,  $A^3$ ,  $A^4$ ,  $A^5$ , L, W, X and m are as defined in claim 1,

or d) reacting a compound of formula (V)





with a compound  $(A^1, A^2, U)N-C(A^3, A^4)-L-M$ , wherein M is mesylate, tosylate, triflate, Cl, Br or I, and  $A^1, A^2, A^3, A^4, A^5, W, U, L, X, m$  and  $n$  are as defined in claim 1, or e) hydrogenating a compound of formula (VI)



wherein V is  $-C\equiv C-$ , and  $A^1, A^2, A^3, A^4, A^5, U, W, L, X, m$  and  $n$  are as defined in claim 1, and optionally converting a compound according to any of claims 1 to 20 to a pharmaceutically acceptable salt, and optionally converting a compound according to any of claims 1 to 20, wherein U is a lone pair, to a corresponding compound wherein U is O.

62. A pharmaceutical composition comprising a compound according to claim 1 and at least one of a pharmaceutically acceptable carrier or pharmaceutically acceptable adjuvant.

63. A method for the treatment and/or prophylaxis of diseases which are associated with OSC such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes, which method comprises administering a compound according to claim 1 to a human being or animal.